We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+40.64%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$587M
AUM Growth
+$37.7M
Cap. Flow
-$98.3M
Cap. Flow %
-16.76%
Top 10 Hldgs %
58.11%
Holding
52
New
10
Increased
8
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$15.8M
2
NGNE icon
Neurogene
NGNE
+$14.2M
3
TRML
Tourmaline Bio
TRML
+$11.5M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$8.68M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$7.03M

Top Sells

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$19.4M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$11.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$11.2M
4
REPL icon
Replimune Group
REPL
+$10.9M
5
ACLX
Arcellx
ACLX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.57B
$7.71M 1.31%
80,000
-85,200
-52% -$8.17M
INSM icon
27
Insmed
INSM
$21.4B
$7M 1.19%
225,912
-168,960
-43% -$4.38M
PBYI icon
28
Puma Biotechnology
PBYI
$404M
$4.73M 0.81%
+1,093,273
New +$3.62M
OCUL icon
29
Ocular Therapeutix
OCUL
$1.79B
$3.12M 0.53%
+700,000
New +$2.07M
SYRE icon
30
Spyre Therapeutics
SYRE
$8.54B
$2.69M 0.46%
+125,000
New +$1.72M
ACLX
31
DELISTED
Arcellx
ACLX
$2.68M 0.46%
48,264
-239,236
-83% -$10.8M
MRUS
32
DELISTED
Merus
MRUS
$550K 0.09%
+20,000
New +$467K
AXSM icon
33
Axsome Therapeutics
AXSM
$11.2B
$395K 0.07%
+4,963
New +$332K
MURA
34
DELISTED
Mural Oncology
MURA
$68.1K 0.01%
+11,509
New +$46.3K
ABOS icon
35
Acumen Pharmaceuticals
ABOS
$155M
– –
-1,074,101
Closed -$4.46M
ACRS icon
36
CALL
Aclaris Therapeutics
ACRS
$726M
– –
-700,000
Closed -$4.79M
ACRS icon
37
Aclaris Therapeutics
ACRS
$726M
– –
-1,691,768
Closed -$11.6M
AKRO
38
DELISTED
Akero Therapeutics
AKRO
– –
-198,500
Closed -$10M
GBIO
39
DELISTED
Generation Bio
GBIO
– –
-102,254
Closed -$3.88M
GOSS icon
40
Gossamer Bio
GOSS
$82.9M
– –
-6,230,272
Closed -$5.19M
HRTX icon
41
Heron Therapeutics
HRTX
$93.9M
– –
-4,737,368
Closed -$4.88M
IGMS
42
DELISTED
IGM Biosciences
IGMS
– –
-615,317
Closed -$5.14M
PTCT icon
43
PTC Therapeutics
PTCT
$5.68B
– –
-500,000
Closed -$11.2M
REPL icon
44
Replimune Group
REPL
$941M
– –
-638,495
Closed -$10.9M
SLDB icon
45
Solid Biosciences
SLDB
$794M
– –
-450,403
Closed -$1.14M
SRPT icon
46
PUT
Sarepta Therapeutics
SRPT
$1.57B
– –
-95,000
Closed -$11.5M
OKUR
47
OnKure Therapeutics
OKUR
$154M
– –
-116,706
Closed -$8.89M
CERE
48
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-215,000
Closed -$4.69M
AMAM
49
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-97,700
Closed -$1.12M
GRCL
50
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-579,667
Closed -$1.67M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Great Point Partners held 52 positions worth $587M, up 6.9% from $549M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $98.3M in Q4 2023, closing 18 positions and reducing 11 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $19.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Abivax worth $16.6M.

  • Great Point Partners's largest Q4 2023 buy was Abivax: 1,550,000 shares worth $16.6M.
  • Great Point Partners added most to Tourmaline Bio in Q4 2023, an estimated $11.5M increase.
  • Great Point Partners's biggest Q4 2023 reduction was Arcellx, cutting an estimated $10.8M.
  • Great Point Partners fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $19.4M.
  • Great Point Partners's ten largest holdings make up 58% of its $587M portfolio in Q4 2023.
  • Great Point Partners opened 10 new positions and closed 18 in Q4 2023.
  • Great Point Partners's portfolio value rose 6.9% quarter-over-quarter to $587M.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.